An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers

Phase 1CompletedNCT00918606

Neothetics, Inc30 enrolled

Overview

An Evaluation of the PK and Safety of LIPO-102 in Healthy Volunteers.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Subcutaneous Adipose Tissue Reduction

Interventions

LIPO-102DRUG

LIPO-102

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male and non pregnant female * 18-55 years old * Sufficient abdominal fat for injections * Signed informed consent Exclusion Criteria: * Known hypersensitivity to study drugs * Treatment with an investigational agent within 30 days before first dose

Locations (1)

Unnamed facility

Baltimore, Maryland, United States

Outcomes

Primary Outcomes

Safety: Laboratory tests, medical exams

Time frame: 4 weeks

Secondary Outcomes

Pharmacokinetics

Time frame: 24 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.